Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    World-Pharmacists-Day-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              ReiThera

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ITALY Italy

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Natural Products Expo

              Participation Not Confirmed

              Update your events

              ReiThera's COVID-19 Vaccine Candidate Enters Phase 1 Clinical Study with First Healthy Volunteer Dosed in Italy

              Contact the Supplier

              Lead Product(s): GRAd-COV2

              Therapeutic Area: Infections and Infectious Diseases Product Name: GRAd-COV2

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 24, 2020

              Details:

              The Phase 1 clinical trial is evaluating the safety and immunogenicity of GRAd-COV2 in 90 healthy volunteers with an objective to select a vaccine dose for further investigation in a Phase 2/3 trial.

              Advent

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ITALY Italy

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Natural Products Expo

              Participation Not Confirmed

              Update your events

              The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine

              Contact the Supplier

              Lead Product(s): ChAdOx1

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Vaccine

              Partner/Sponsor/Collaborator: The Jenner Institute, Oxford University

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 11, 2020

              Details:

              The Jenner Institute at the University of Oxford has agreed a contract with Advent Srl, to produce the first batch of the novel coronavirus vaccine ChAdOx1 nCoV-19 for clinical testing.

              PharmaCompass__DigitalAd